UV1
- Generic Name
- UV1
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit
- Associated Conditions
- -
- Associated Therapies
- -
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 30
- Registration Number
- NCT03538314
- Locations
- 🇺🇸
John Wayne Cancer Center, Santa Monica, California, United States
🇺🇸St. Luke's University Health Network, Easton, Pennsylvania, United States
🇺🇸University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath